Chemotherapy use in stage III colon cancer: A National Cancer Database analysis

Therapeutic Advances in Medical Oncology

Volumn 7, Issue 5, 2015, Pages 244-251

  Upadhyay, Smrity ^a   Dahal, Sumit ^b   Bhatt, Vijaya Raj ^c   Khanal, Nabin ^d   Silberstein, Peter T ^d  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INTERFAITH MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Disparities; Stage III colon cancer

Indexed keywords

ADULT; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CAUCASIAN; COLON CANCER; COMORBIDITY; CONFERENCE PAPER; EDUCATIONAL STATUS; FEMALE; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; MEDICARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOCIOECONOMICS;

EID: 84940191842     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834015587867     Document Type: Article

References (47)

1. Andre T. Boni C. Mounedji-Boudiaf L. Navarro M. Tabernero J. Hickish T. et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350: 2343–2351.
2. Andre T. Colin P. Louvet C. Gamelin E. Bouche O. Achille E. et al (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21: 2896–2903.
3. Baldwin L. Dobie S. Billingsley K. Cai Y. Wright G. Dominitz J. et al (2005) Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 97: 1211–1220.
4. Bilimoria K. Stewart A. Winchester D. Ko C. (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15: 683–690.
5. Boland G. Chang G. Haynes A. Chiang Y. Chagpar R. Xing Y. et al (2013) Association between Adherence to national comprehensive cancer network treatment guidelines and improved survival in patients with colon cancer. Cancer 119: 1593–1601.
6. Buyse M. Zeleniuch-Jacquotte A. Chalmers T. (1988) Adjuvant Therapy of colorectal cancer. Why we still don't know. JAMA 259: 3571–3578.
7. Chau I. Norman A. Cunningham D. Tait D. Ross P. Iveson T. et al (2005) A Randomised comparison between 6 months of bolus fluorouracil / leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 16: 549–557.
8. Conway W. Faries M. Nicholl M. Terando A. Glass E. Sim M. et al (2009) Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol 16: 1548–1552.
9. Edge S. Byrd D. Compton C. Fritz A. Greene F. Trotti A. (2010) Colon and rectum. In: Ed. Edge S. Byrd D. Compton C., AJCC Cancer Staging Manual, 7th edn. New York: Springer-Verlag, pp. 143–164.
10. Engstrom P. Arnoletti J. Benson A. 3rd Chen Y. Choti M. Cooper H. et al (2009) NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw 7: 778–831.
11. Extermann M. Hurria A. (2007) Comprehensive Geriatric assessment for older patients with cancer. J Clin Oncol 25: 1824–1831.
12. Glimelius B. Dahl O. Cedermark B. Jakobsen A. Bentzen S. Starkhammar H. et al (2005) Adjuvant Chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 44: 904–912.
13. Haller D. Cassidy J. Tabernero J. Maroun J. de Braud F. Price T. et al (2010) Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): impact of age on disease-free survival (DFS). J Clin Oncol 28: 3521.
14. Haller D. Catalano P. Macdonald J. O'Rourke M. Frontiera M. Jackson D. et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23: 8671–8678.
15. Hanna N. Onukwugha E. Choti M. Davidoff A. Zuckerman I. Hsu V. et al (2012) Comparative Analysis of various prognostic nodal factors, adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using surveillance, epidemiology and end results (SEER)-Medicare Data. Colorectal Dis 14: 48–55.
16. Marsoni S. (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939–944.
17. Jemal A. Bray F. Center M. Ferlay J. Ward E. Forman D. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.
18. Jessup J. Stewart A. Greene F. Minsky B. (2005) Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 294: 2703–2711.
19. Jullumstro E. Lydersen S. Moller B. Dahl O. Edna T. (2009) Duration of symptoms, stage at diagnosis and relative survival in colon and rectal cancer. Eur J Cancer 45: 2383–2390.
20. Kuebler J. Wieand H. O'Connell M. Smith R. Colangelo L. Yothers G. et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25: 2198–2204.
21. Laurie J. Moertel C. Fleming T. Wieand H. Leigh J. Rubin J. et al (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 7: 1447–1456.
22. Lembersky B. Wieand H. Petrelli N. O'Connell M. Colangelo L. Smith R. et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24: 2059–2064.
23. Mahoney T. Kuo Y. Topilow A. Davis J. (2000) Stage III colon cancers: why adjuvant chemotherapy is not offered to elderly patients. Arch Surg 135: 182–185.
24. McCleary N. Meyerhardt J. Green E. Yothers G. de Gramont A. van Cutsem E. et al (2013) Impact of age on the efficacy of newer adjuvant therapies in patients with stage II / III colon cancer: findings from the Accent Database. J Clin Oncol 31: 2600–2606.
25. Moertel C. Fleming T. Macdonald J. Haller D. Laurie J. Goodman P. et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352–358.
26. NIH Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264: 1444–1450.
27. Moertel C. Fleming T. Macdonald J. Haller D. Laurie J. Tangen C. et al. (1995). Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122 (5): 321–326.
28. Peeters M. Haller D. (1999) Therapy for early-stage colorectal cancer. Oncology 13: 307–315; discussion 315–307: 320–301.
29. Phelip J. Molinie F. Delafosse P. Launoy G. Tretarre B. Bara S. et al (2010) A Population-Based study of adjuvant chemotherapy for stage-II and -III colon cancers. Gastroenterol Clin Biol 34: 144–149.
30. Poplin E. Benedetti J. Estes N. Haller D. Mayer R. Goldberg R. et al (2005) Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 23: 1819–1825.
31. Potosky A. Harlan L. Kaplan R. Johnson K. Lynch C. (2002) Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20: 1192–1202.
32. Ramjaun A. Nassif M. Krotneva S. Huang A. Meguerditchian A. (2013) Improved Targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol 4: 271–281.
33. Roetzheim R. Pal N. Gonzalez E. Ferrante J. van Durme D. Krischer J. (2000) Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 90: 1746–1754.
34. Saltz L. Niedzwiecki D. Hollis D. Goldberg R. Hantel A. Thomas J. et al (2007) Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25: 3456–3461.
35. Sanoff H. Carpenter W. Sturmer T. Goldberg R. Martin C. Fine J. et al (2012) Effect of adjuvant chemotherapy on survival of patients with stage iii colon cancer diagnosed after age 75 years. J Clin Oncol 30: 2624–2634.
36. Sargent D. Goldberg R. Jacobson S. Macdonald J. Labianca R. Haller D. et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345: 1091–1097.
37. Schrag D. Cramer L. Bach P. Begg C. (2001) Age and adjuvant chemotherapy use after surgery for stage III Colon cancer. J Natl Cancer Instit 93: 850–857.
38. Siegel R. Desantis C. Jemal A. (2014 a) Colorectal cancer statistics, 2014. CA Cancer J Clin 64: 104–117.
39. Siegel R. Ma J. Zou Z. Jemal A. (2014 b) Cancer statistics, 2014. CA Cancer J Clin 64: 9–29.
40. Sundararajan V. Grann V. Jacobson J. Ahsan H. Neugut A. (2001) Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 7: 213–218.
41. Tournigand C. Andre T. Bonnetain F. Chibaudel B. Lledo G. Hickish T. et al (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and Elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the Adjuvant Treatment of Colon Cancer Trial. J Clin Oncol 30: 3353–3360.
42. Tsai S. Balch C. Lange J. (2010) Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol 7: 148–152.
43. Tsikitis V. Larson D. Huebner M. Lohse C. Thompson P. (2014) Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14: 336.
44. Twelves C. Wong A. Nowacki M. Abt M. Burris H. 3rd Carrato A. et al (2005) Capecitabine as Adjuvant treatment for stage III colon cancer. N Engl J Med 352: 2696–2704.
45. Vaneenwyk J. Campo J. Ossiander E. (2002) Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. Cancer 95: 39–46.
46. Wolmark N. Rockette H. Fisher B. Wickerham D. Redmond C. Fisher E. et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 11: 1879–1887.
47. Yothers G. O'Connell M. Allegra C. Kuebler J. Colangelo L. Petrelli N. et al (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29: 3768–3774.